Product Description: Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Kyriakos P. Papadopoulos, et al. Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).
CAS Number: 2640981-19-5
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
